What caused the decline in breast cancer mortality in the united kingdom?
- 56 Downloads
The marked improvement in breast cancer mortality in the United Kingdom (UK) has attracted worldwide interest. To understand the details of this phenomenon the morbidity and mortality rates of breast cancer in the UK during the past 30 years were analyzed.
The official publications and statistical data were available and downloaded at the official UK Web sites of the National Health Service, National Statistics and Cancer Research Organization. Parts of the data were obtained directly from the National Cancer Intelligence Centre of UK.
After the beginning of breast screening the morbidity of the subject age group soared up to the level of an age group that was 10 years older. Noninvasive carcinoma was often discovered in the subject age group after the beginning of breast screening and constituted 8.3% of all cases. The mortality rates, however, began to decrease before the start of screening and fell clearly even in age groups other than that of the study group and particularly in elderly women.
Not only the prevalence of breast screening but also the increase of early stage cancer in all age groups have probably resulted from improvements in diagnostic technology and heightened social interest and awareness. In addition, the development of adjuvant endocrine therapy must have influenced the evident improvement in mortality of breast cancer in the UK.
Key wordsBreast screening Breast cancer Mortality United Kingdom
Invasive ductal carcinoma
Ductal carcinomain situ
International Agency for Research on Cancer
Unable to display preview. Download preview PDF.
- 7).Personal information from Mr. Nicola Cooper, a Senior Cancer Epidemiologist, National Cancer Intelligence Centre, Office for National Statistics, UK.Google Scholar
- 8).NHS Breast Screening Programme: Annual Review 1999 (from ref. 8).Google Scholar
- 9).(No authors sited): Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organization.Lancet 1:836–840,1985.Google Scholar
- 11).(No authors sited): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.Lancet 2:171–175,1987.Google Scholar
- 15).International Agency for Research for Cancer (IARC): Handbooks on Cancer Prevention, volume 7: Breast Cancer Screening, IARC, Lyons, 2002.Google Scholar
- 16).NHS Breast Screening Programme: Annual Review 2001. Informing choice in breast screening (from ref. 8).Google Scholar
- 18).Otto SJ, Fracheboud J, Looman CW, Broeders MJ, Boer R, Hendriks JH, Verbek AL, de Koning HJ, National Evaluation Team for Breast Screening: Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systemic review.Lancet 361:1411–1417, 2003.PubMedCrossRefGoogle Scholar
Internet Based References
- a).httpy/www.cancerscreening.nhs.uk/index.htmlGoogle Scholar
- b).http://www.cancerscreening.nhs.uk/breastscreen/ publications/Google Scholar
- c).http://www.statistics.gov.uk/STATBASE/Product. asp?vlnk=8843Google Scholar
- d).http://www.statistics.gov.uk/downloads/theme_ health/cancertrends_5099.pdfGoogle Scholar
- e).http://www.cancerresearchuk.org/aboutcancerGoogle Scholar